KF
CYTK icon

Krilogy Financial’s Cytokinetics CYTK Stock Holding History

Krilogy Financial’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-200
Closed -$2K – 775
2017
Q4 		$2K Sell
200
-200
-50% -$2.27K ﹤0.01% 682
2017
Q3 		$6K Sell
400
-100
-20% -$1.37K ﹤0.01% 628
2017
Q2 		$6K Hold
500
– – ﹤0.01% 575
2017
Q1 		$6K Hold
500
– – ﹤0.01% 561
2016
Q4 		$6K Sell
500
-200
-29% -$2.12K ﹤0.01% 561
2016
Q3 		$6K Hold
700
– – ﹤0.01% 578
2016
Q2 		$7K Hold
700
– – ﹤0.01% 574
2016
Q1 		$5K Hold
700
– – ﹤0.01% 531
2015
Q4 		$7K Hold
700
– – 0.01% 287
2015
Q3 		$5K Buy
+700
New +$4.78K ﹤0.01% 461

Other funds holding CYTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LPU
Lansdowne Partners (UK) London, United Kingdom $1.87B AUM 61.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Krilogy Financial's CYTK Position: Q1 2018 in Review

Krilogy Financial sold out of Cytokinetics (CYTK) in Q1 2018, closing a stake of 200 shares — an estimated $2K sold.

Krilogy Financial first reported a position in CYTK in Q3 2015 and held it in 10 quarters. The position peaked at $7K in Q2 2016. 127 funds tracked by Wall St. Rank hold CYTK as of Q1 2018.

  • Krilogy Financial reported no remaining Cytokinetics position as of Q1 2018 after selling out during the quarter.
  • Krilogy Financial sold 200 Cytokinetics shares in Q1 2018, an estimated $2K.
  • Krilogy Financial first reported a position in Cytokinetics in Q3 2015 and held it in 10 quarters.
  • Krilogy Financial's Cytokinetics position peaked at $7K in Q2 2016.
  • 127 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2018.

Based on Krilogy Financial's 13F filing for Q1 2018, filed 15 May 2018.